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ABSTRACT
We recently completed a phase I/IIa trial of RNActive CV9201, a novel mRNA-based therapeutic vaccine
targeting ﬁve tumor-associated antigens in non-small cell lung cancer (NSCLC) patients. The aim of the
study presented here was to comprehensively analyze changes in peripheral blood during the vaccination
period and to generate hypotheses facilitating the identiﬁcation of potential biomarkers correlating with
differential clinical outcomes post RNActive immunotherapy. We performed whole-genome expression
proﬁling in a subgroup of 22 stage IV NSCLC patients before and after initiation of treatment with CV9201.
Utilizing an analytic approach based on blood transcriptional modules (BTMs), a previously described,
sensitive tool for blood transcriptome data analysis, patients segregated into two major clusters based on
transcriptional changes post RNActive treatment. The ﬁrst group of patients was characterized by the
upregulation of an expression signature associated with myeloid cells and inﬂammation, whereas the
other group exhibited an expression signature associated with T and NK cells. Patients with an enrichment
of T and NK cell modules after treatment compared to baseline exhibited signiﬁcantly longer progression-
free and overall survival compared to patients with an upregulation of myeloid cell and inﬂammatory
modules. Notably, these gene expression signatures were mutually exclusive and inversely correlated.
Furthermore, our ﬁndings correlated with phenotypic data derived by ﬂow cytometry as well as the
neutrophil-to-lymphocyte ratio. Our study thus demonstrates non-overlapping, distinct transcriptional
proﬁles correlating with survival warranting further validation for the development of biomarker
candidates for mRNA-based immunotherapy.
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Introduction
Lung cancer is the leading cause of cancer-related deaths world
wide and 85–90% of those malignancies are classiﬁed as non-
small cell lung cancer (NSCLC).1 For decades, clinical out-
comes of patients with advanced NSCLC were poor with 5-y
survival rates of less than 5%.2,3 However, immunotherapeutic
approaches, in particular checkpoint inhibitors, have recently
dramatically impacted the ﬁeld of cancer therapy.4 The aim of
immunotherapy is to induce and activate host immune
responses against the tumor.5 Antibodies blocking the interac-
tion of inhibitory T cell receptors CTLA-4 or PD-1 with their
ligands were demonstrated to improve survival rates in patients
with metastasized melanoma and NSCLC.6 In addition,
encouraging long-lasting responses have been observed in a
variety of solid tumors and hematologic malignancies after
treatment with antibodies blocking PD-1 or PD-L1.7
Whereas these clinical results are highly encouraging, a
substantial portion of patients fail to beneﬁt from checkpoint
inhibition treatment. Furthermore, immune-mediated adverse
effects occur even in patients who do not respond to treat-
ment.8 Combined blockade of PD-1 and CTLA-4 has resulted
in improved response rate and progression-free survival in mel-
anoma patients compared to CTLA-4 blockade alone and in
patients with PD-L1 negative tumors also compared to PD-1
blockade. However, severe immune-mediated side effects were
more frequent with the combined treatment.9 A likely cause for
immune-mediated adverse effects is non-speciﬁc T cell activa-
tion and inhibition of regulatory CD4C T cells.10 Also, check-
point inhibition requires that tumor-speciﬁc T cells are present
prior to the treatment in order to result in antitumor activity.4
Central immunological tolerance mechanisms delete many T
cells with high avidities to tumor antigens, resulting in a
depleted tumor-speciﬁc T cell repertoire too limited to robustly
control the tumor.5 Nonetheless, spontaneous T cell responses
against tumor antigens frequently develop in most cancer
patients11 and the depleted T cell repertoire can still be
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effectively harnessed for clinical beneﬁt. In this context, active
therapeutic vaccination, which aims at priming novel tumor-
speciﬁc immune responses in addition to boosting pre-existing
ones, could play a critical role to alleviate this problem.12 Due
to its speciﬁc mechanism of action, active immunotherapy
could enhance the antitumor effects of checkpoint inhibition
without the substantial increase in immune-mediated adverse
effects seen with combined checkpoint blockade.
Among vaccination platforms currently under evaluation in
clinical trials, mRNA-based vaccines represent highly attractive
candidates.13-15 RNActive is a novel mRNA-based vaccination
technology with self-adjuvanting activity, engineered with
chemically unmodiﬁed, natural nucleotides. The RNActive
cancer immunotherapies employed in our studies consist of
two components: free and protamine-complexed, sequence-
optimized, full-length mRNA to support both high antigen
expression and immune stimulation, predominantly mediated
by toll-like receptor 7 (TLR-7).16-18 In pre-clinical experiments,
intradermal injection of the two-component mRNA vaccines
encoding tumor-associated antigens induced boostable and
balanced effector and memory immune responses including
antigen-speciﬁc CD4C T helper cells, cytotoxic CD8C T cells,
memory T cells, and antibody-producing B cells. These
responses were associated with strong antitumor effects and
complete protection against antigen-positive tumor cells.19-24
Further pre-clinical studies provided evidence for synergistic
effects of the two-component mRNA vaccine combined with
radio therapy as well as checkpoint-inhibiting anti-CTLA-4
antibodies.18,25
Moreover, we have successfully completed a ﬁrst-in-man
phase I/IIa trial in patients with advanced castration-resistant
prostate cancer. This study showed that repeated immuniza-
tions with two-component mRNA vaccines, encoding prostate
cancer-associated antigens, induced vaccine-speciﬁc immune
responses and were well tolerated showing a favorable safety
proﬁle.26 We have also successfully completed a phase I/IIa
trial, conducted in patients with advanced NSCLC. In this trial,
patients were treated with RNActive CV9201 vaccine, which
targets ﬁve known NSCLC-associated cancer antigens: cancer/
testis antigen 1B (New York esophageal squamous cell carci-
noma, NY-ESO1), melanoma antigen family C1 (MAGE-C1),
MAGE-C2, baculoviral inhibitor of apoptosis repeat-containing
5 (survivin), and trophoblast glycoprotein (5T4).
These pioneering studies represent some of the ﬁrst human
trials employing mRNA-based vaccine technology to treat
highly aggressive cancer, such as NSCLC. To investigate poten-
tial mechanisms of action and to identify immune correlates of
protection, we sought to comprehensively monitor gene
expression changes post vaccination. We therefore performed
whole-genome transcriptome analyses of peripheral blood
mononuclear cell (PBMC) samples derived before and after
initiation of mRNA vaccination in NSCLC patients. Gene
expression data can elucidate the underlying biology of vac-
cine-associated changes in blood, including alterations of cell
subset composition and biological processes including signaling
pathways, proliferation, apoptosis, cytotoxicity and others. Fur-
thermore, transcriptome analyses are frequently performed in
vaccine studies to identify correlates of immune protection,
which can be further assessed as potential biomarker
candidates.27-31 Samples for gene expression proﬁling described
in this manuscript were available from 22 of the 32 stage IV
NSCLC patients enrolled in the phase IIa part of the clinical
trial. These patients had been treated with CV9201 at a dose of
320 mg of each individual mRNA component encoding one of
the ﬁve antigens and at a total dose of 1,600 mg per application.
Since the primary aim of this ﬁrst-in man dose escalation clini-
cal trial was to assess safety and immunogenicity of CV9201,
no placebo arm was included in the study. The aim of this
exploratory gene expression proﬁling analysis was to generate
hypotheses regarding biological changes in peripheral blood
after repeated mRNA vaccinations compared to baseline.
Utilizing blood transcriptional modules (BTMs) previously
established by Li et al.32, we show an enrichment of distinct
modules in the post vaccine samples. In comparison with base-
line, we found an upregulation of transcriptional modules con-
sistent with myeloid cells and inﬂammation in one group of
patients and an upregulation of T and NK cell modules in
another group of patients. Notably, these transcriptional
changes were mutually exclusive and associated with different
clinical outcomes. The transcriptional signatures identiﬁed in
our study require further evaluation in controlled studies to
explore their potential as biomarker candidates associated with
mRNA-based immunotherapy. Moreover, these data will help
inform future immunotherapeutic approaches in cancer trials.
Results
Enrichment of transcriptional modules consistent with
adaptive immunity post vaccination
Demographic and clinical data of the 22 stage IV NSCLC
patients investigated in this gene expression study is provided
in Table 1 and Table S1. Patients received intradermal vaccina-
tions at weeks 1, 2, 3, 5 and 7 with a total dose of 1,600 mg
mRNA per vaccination (320 mg per antigen). Blood sampling
by venipuncture for PBMC analysis was performed at day 0
(baseline), week 5 (2 weeks post third vaccination) and week 9
(2 weeks post 5th vaccination). Within the ﬁrst 17 mo after ini-
tiation of mRNA treatment, 15 deaths had been reported in our
study subgroup (Fig. S1A). Notably, the next death occurred 15
mo later and six other patients were still alive at their ﬁnal
Table 1. Demographic overview of the investigated NSCLC patient cohort.
IQR – interquartile range. N.D. – not determined.
Gender
female 45.5% (10/22)
male 54.5% (12/22)
Age
[years] (IQR) 64 (55.75 – 73.25)
Tumor
Adenocarcinoma 63.6% (14/22)
Squamous cell carcinoma 18.2% (4/22)
Large cell carcinoma 9.1% (2/22)
Mixed 4.5% (1/22)
N.D. 4.5% (1/22)
Metastasis
Lymph node 63.6% (14/22)
Bone 18.2% (4/22)
Overall survival
[days] (IQR) 345 (194.25–1049.75)
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follow-up visit. Due to this gap of 15 mo, we deﬁned patients
with a survival exceeding 30 mo as long-term survivors,
whereas the remaining patients were classiﬁed as short-term
survivors. The median survival of the long-term survivors at
their last visit was 35 mo, whereas the median survival of the
short-term survivors was 7.4 mo. We ﬁrst sought to identify
gene expression differences between short-term and long-term
survivors.
Traditionally, supervised analysis of whole-genome tran-
scriptional data frequently involves the identiﬁcation of differ-
entially expressed genes, followed by pathway and annotation
enrichment analyses. We initially sought to apply this approach
to our expression data. However, after correcting for multiple
testing, we were unable to identify differentially expressed
genes in a number of comparisons (data not shown). A likely
explanation could be that the investigated subset of patients
was too heterogeneous with regards to histological characteris-
tics of the tumor, the prior anticancer treatment and concomi-
tant diseases of the patients, resulting in a high transcriptional
heterogeneity. To accommodate the high degree of heterogene-
ity in our samples, we sought to apply a modular approach to
our expression data analysis by summarizing coordinately
expressed genes into modules. Such approaches provide
increased sensitivity over identifying differentially expressed
genes on a gene by gene approach by statistical and/or fold
change methods.33 We adopted the BTMs developed by Li
et al. since these modules were speciﬁcally designed to analyze
human blood transcriptomes in the context of vaccine-elicited
immune responses.32
To investigate the transcriptional differences between short-
term and long-term survivors, we performed gene set enrich-
ment analyses (GSEA) utilizing BTMs as gene sets. We found
that long-term survivors exhibited an enrichment of transcrip-
tional modules associated with effector lymphocytes, in partic-
ular T cells (Figs. S1B–D). This enrichment of T cell modules
was observed at both post vaccine time points (week 5 and
week 9) and also at baseline (week 0). In addition, NK cell and
B cell modules were enriched in long-term survivors at weeks 5
and 9, respectively (Figs. S1C and D).
We next sought to determine transcriptional changes post
therapeutic vaccination with CV9201 in all 22 subjects. Pre-
ranked transcript lists were generated based on paired t-test
statistics comparing week 5 samples and week 9 samples with
their matching week 0 samples. We performed GSEA on these
pre-ranked lists utilizing BTMs as gene sets. Among the top 15
most enriched BTMs at week 5, there was an enrichment of six
modules representing T cells, including one module consisting of
genes speciﬁc for Th2 differentiation and another module with
cell cycle genes speciﬁc to activated CD4C T cells (Fig. 1B). We
also found four modules reﬂecting B cells including one module
containing genes highly expressed in plasma cells and genes
encoding immunoglobulins (Fig. 1B). The enrichment of B cell
modules was partially retained in the week 9 samples (Fig. 1B).
Notably, week 0 in comparison with week 5 samples exhib-
ited an enrichment of BTMs consistent with myeloid cells, den-
dritic cells, antigen presentation and inﬂammation (Fig. 1A). In
contrast, the baseline week 0 to week 9 revealed a relative enrich-
ment of modules associated with cell cycle and transcriptional
activation. The data indicate a transient upregulation of
transcriptional modules consistent with adaptive immune
responses post therapeutic vaccination and a downregulation of
myeloid cell- and inﬂammation-related modules. Furthermore,
these data show that the use of BTMs in combination with
GSEA represents a sensitive analytical tool to detect post treat-
ment differences in a subgroup of heterogeneous patients.
Distinct patient clustering based on BTM activity changes
at week 5
In addition to the supervised approaches, we also applied an
unbiased approach to expression data analysis. We ﬁrst calcu-
lated the BTM activity scores for each of the 346 transcriptional
modules. These BTM activity scores represent the mean expres-
sion values of all genes contained in a single module. We used
hierarchical clustering to identify changes in module activity
scores between week 0 and 5. Clustering was performed for
both subjects and modules. Notably, patients segregated into
two distinct groups (Fig. 2A). Importantly, the clustering of
patients was predominantly driven by two individual sets of
modules. One cluster of modules predominantly contained T
and NK cell modules, whereas the other cluster contained mod-
ules reﬂecting myeloid cells, antigen presentation and immune
activation. We furthermore noticed that patients upregulating
T and NK cell modules at week 5 were further divided into two
sub-clusters, based on their expression pattern of cell cycle
modules (Fig. 2A). We investigated whether the patient cluster-
ing was associated with distinct histological subtypes of NSCLC
(Table S1) and were unable to identify such relationships.
We next addressed the question if clustering of patients
could be conﬁrmed using principal component analysis (PCA),
a widely used method to visualize high-dimension data. Analo-
gously to our unsupervised hierarchical clustering analysis, we
used week 5 to week 0 differences of the 346 BTM activity
scores as variable values. The ﬁrst two principal components
cumulatively accounted for approximately 51% of variance in
our data set. The loading factors of PC1 and PC2 revealed that
most of the variance could be attributed to cell cycle modules
(Fig. 2D). Thus, patients in PC1 and PC2 space mostly sepa-
rated based on their differential expression of genes associated
with cell cycle and mitosis processes. In addition to these, we
observed modules for T and NK cells contributing to PC1 and
PC2 as well as modules associated with myeloid and antigen-
presenting cells (Fig. 2D). Using the same data set, we also clus-
tered the modules and found distinct clustering of the three sets
of BTMs responsible for the clustering of patients (Fig. 2C). In
fact, BTMs reﬂecting monocytes and immune activation on the
one hand and BTMs representing T and NK cells on the other
hand clustered in opposite corners in the PC1/PC2 projection.
We were thus able to conﬁrm the results from the hierarchical
clustering using PCA as an independent analysis method.
Non-overlapping transcriptional changes in segregated
patients after CV9201 treatment
The results from the unsupervised clustering analyses strongly
suggested divergent transcriptional changes in distinct subsets
of patients. To gain additional insight into the transcriptional
changes after vaccination, we separated the patients into two
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groups according to their clustering pattern. For each of these
two groups, we generated ranked transcript lists based on
paired t-test statistics comparing week 5 with their matching
week 0 samples. GSEA was performed on these lists using
BTMs as gene sets. As expected, at week 5, patients belonging
to cluster 1 exhibited a strong upregulation of transcriptional
modules associated with monocytes, myeloid cells, antigen pre-
sentation and immune activation (Fig. 3A). To gain further
insight into the single genes enriched within these modules, we
extracted the leading edge genes of the top 10 most enriched
BTMs. Among the transcripts most frequently enriched in the
top modules, we identiﬁed genes associated with myeloid cells,
including genes encoding for toll-like receptors 2 and 5 (TLR2,
TLR5), chemokine receptor type 1 (CCR1), formyl peptide
receptors 1 and 2 (FPR1, FPR2), colony stimulating factor 3
receptor (CSF3R) and complement component 5a receptor 1
(C5AR1) (Figs. S2A and B). As expected, all of these genes
were upregulated in cluster 1 patients at weeks 5 and 9 com-
pared to baseline (Fig. S2B).
In contrast, the top 10 most enriched modules in patients
belonging to cluster 2 were characterized by upregulation of
BTMs associated with T cells, NK cell and B cells. In addition,
there was also one cell cycle BTM within the top 15 enriched
BTMs at week 5 in patients of cluster 2. In this group of
patients, the myeloid-leading edge genes were temporarily
downregulated at week 5 compared to baseline except for NFE2
(Fig. S2A). Based on the patient clustering results (Fig. 2A), we
further sought to dissect patients within cluster 2 and divided
them into subgroups 2a and 2b. Transcriptional upregulation of
T and NK cell modules were found in both subclusters
(Figs. 3C and D). However, upregulation of B cell modules was
only found in patients belonging to cluster 2a, whereas cell cycle
and mitosis modules were only enriched in cluster 2b patients.
The distinct patient clustering driven by myeloid or T and
NK cell modules suggested that these transcriptional changes
were mutually exclusive. To test this hypothesis, we ﬁrst calcu-
lated the week 5 to 0 differences for each of these two sets of
BTMs. We then determined the mean of all BTM week 5 to 0
Figure 1. Transcriptional modules consistent with an adaptive immune response proﬁle are enriched at week 5 post initiation of CV9201 treatment. Gene set enrichment
analyses contrasting baseline week 0 samples to post vaccine week 5 samples (A), and samples derived from week 5 to 0 (B), week 0 to 9 (C) and week 9 to 0 (D), respec-
tively. Genes were pre-ranked based on t values from paired Student’s t-tests. NES – Normalized enrichment scores.
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differences contained in the myeloid cluster and the T and NK
cell cluster. Correlation analysis revealed a highly signiﬁcant,
inverse relationship between these two means (Fig. 3E). These
results therefore indicate that in our subjects, the upregulation
of BTMs consistent with myeloid cells, or with T and NK cells
is mutually exclusive. Thus, segregated patients were character-
ized by an enrichment of non-overlapping transcriptional mod-
ules post vaccination.
Prolonged progression-free and overall survival in
patients with NK and T cell BTM enrichment at week 5
Increased expression of genes associated with monocytes and
other myeloid cells could indicate rising levels of circulating
myeloid-derived suppressor cells (MDSCs). These heteroge-
neous subsets of immature myeloid cells have been described
in NSCLC patients and were linked with unfavorable clinical
outcomes.34-36 Furthermore, transcriptional proﬁling studies
performed in PBMCs derived from NSCLC patients indicated a
positive correlation between survival and the expression of T
cell-associated genes.37-39 We therefore hypothesized that
patients belonging to cluster 2 with a higher activity of T and
NK cell modules after vaccination should exhibit a better clini-
cal outcome compared to patients in cluster 1. This was indeed
the case as all patients in our cohort with a higher activity of
myeloid cells at week 5 compared to week 0 were short-term
survivors and died within less than a year (Figs. 4A and B). We
found similar results when we compared the progression-free
Figure 2. Transcriptional changes post treatment cluster patients into distinct groups. (A) Week 5 to 0 BTM activity score differences were calculated and unsupervised hierarchi-
cal clustering was performed. Red indicates up- and blue indicates downregulation of BTM activity scores at week 5 compared to 0. (B, C) Principal component analysis was per-
formed on week 5 to 0 BTM activity scores. Patient (B) and module clustering (C) in PCA space are shown. (D) Weighting coefﬁcients of BTMs for PC1 and PC2 are shown.
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survival between cluster 1 and cluster 2 patients (Figs. 4C and
D). In our cohort comprising 22 patients, there were seven
patients with a prolonged survival exceeding 30 mo. All of these
long-term survivors were part of patient cluster 2. We were
thus able to identify a signiﬁcant difference in overall and pro-
gression-free survival between patients belonging to cluster 1
and cluster 2 (Figs. 4B and D).
Changes in the transcriptional signature correlate with
changes in lymphocyte subsets and neutrophil/lymphocyte
ratio
The transcriptional changes at week 5 post treatment could
either be the result of changes in the cellular composition in
peripheral blood or alternatively indicate transcriptional activa-
tion of distinct leukocyte subsets or a combination of both. To
address this question, we performed correlation analyses
between selected BTM activity scores and lymphocyte pheno-
typing data measured by ﬂow cytometry. Differentiation states
of CD4C and CD8C T cells were assessed based on their cell
surface expression of CCR7 and CD45RA, and we deﬁned
effector memory T cells as CCR7¡CD45RA¡ cells.40,41 We fur-
ther dissected these effector memory cells based on their
expression patterns of CD27 and CD28. Intriguingly, changes
in T cell module activity scores derived from the top 15 most
enriched BTMs in patient cluster 2a (Fig. 3C) were positively
correlated with absolute and relative changes of CD27CCD28¡
effector memory CD8C T cells (Fig. 5A). Consistent with this
ﬁnding, a number of genes associated with T effector functions
were enriched in cluster 2 patients at week 5 including CCL5,
CTSW, the genes encoding for gramzymes A, B, H, M and K
(GZMA, GZMB, GZMH, GZMM, GZMK), Perforin (PRF1),
KLRF1 and the transcription factors T-bet (TBX21) and LEF1
(Figs. S2C and D). Similarly, there was a positive correlation
between changes in B cell module activity scores and changes
in relative and absolute B cell numbers (Fig. 5B). Although ﬂow
cytometric data were not obtained during the course of the clin-
ical trial to allow precise identiﬁcation of myeloid cells,
CD16CCD3¡CD 56¡ lymphocytes to a large degree consist of
HLA-DR-expressing myeloid cells as well as some NK cells
devoid of CD56 (personal observation). Using these criteria, we
were able to identify a positive association between changes in
myeloid BTM scores with relative and absolute changes in
CD16CCD3¡CD56¡ cells (Fig. 5C).
In addition, the cellular composition of peripheral blood, in
particular lymphocyte and neutrophil frequencies, was
routinely assessed during the clinical trial as safety parameters
by differential blood count. We determined the neutrophil-to-
lymphocyte (N/L) ratio, a previously described marker with
prognostic value in various cancer indications, including
NSCLC.42-46 Module activity changes in cluster 2a were linked
to the changes in lymphocyte frequencies and inversely
correlated with changes in the N/L ratio (Fig. 5D). Conversely,
transcriptional changes in BTM cluster 1 were negatively
associated with changes in lymphocyte percentages but
positively correlated with changes in the N/L ratio (Fig. 5E). In
summary, these data suggest that the detected transcriptional
changes may be in part the result of changes in the cellular
Figure 3. Transcriptional changes in segregated patients post CV9201 treatment are non-overlapping. Gene set enrichment analyses contrasting post vaccine week 5 to
week 0 samples was performed utilizing pre-ranked gene lists based on t values from paired Student’s t-tests. Patient groups were derived from the hierarchical clustering
analysis shown in Fig. 2A. Normalized enrichment scores of the top 10 most enriched BTMs are shown for patients from cluster 1 (A), complete cluster 2 (B), cluster 2a (C)
and cluster 2b (D). (E) Mean of week 5 to 0 BTM activity score changes were calculated for T and NK cell modules as well as myeloid cell and inﬂammation modules. Pear-
son correlation analysis was performed.
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composition of peripheral blood cells. Furthermore, by
demonstrating correlations with the N/L ratio, we show that
our transcriptional signatures are consistent with previously
established prognostic biomarkers in cancer.
Discussion
Active cancer immunotherapy based on CureVac’s mRNA tech-
nology was previously shown to be safe and well tolerated and
potently induced vaccine antigen-speciﬁc immune responses.26
Similar observations were made in the clinical trial of CV9201 in
NSCLC described here (manuscript in preparation). In a subset
of this NSCLC trial, we sought to identify transcriptional differ-
ences post vaccination in 22 stage IV lung cancer patients. The
aim of the study was to generate hypotheses regarding underly-
ing biological processes associated with protection detectable in
peripheral blood and to identify potential biomarker candidates
for mRNA-based immunotherapies in NSCLC.
Whole-genome transcriptional proﬁling is a widely used
approach to identify molecular signatures correlating with vac-
cine-induced immune protection and to generate hypotheses
for biomarkers in clinical cancer trials.47 Since transcriptome
proﬁling by microarrays was introduced approximately 15 y
ago, many different analysis tools have been developed to pro-
cess the data.48,49 Traditional supervised approaches to analyze
transcriptional data frequently involve identifying differentially
expressed genes followed by pathway and annotation
enrichment analyses.50 Although pathway analyses for gene
expression data have been helpful to elucidate the biological
context in many experimental settings, we were confronted
with a number of limitations when applying this approach to
our PBMC transcriptome data. PBMC transcriptomes contain
expression signals from a variety of cells, which limits the sensi-
tivity of pathway analyses. Also, due to the heterogeneous
nature of NSCLC disease,1 we expected and indeed encoun-
tered a substantial degree of additional heterogeneity in our
samples. As pointed out by Li et al., a substantial part of the
knowledge contained in pathway databases are of limited value
to assess PBMC transcriptomes, due to the sometimes artiﬁcial
experimental conditions, in which pathways had been identi-
ﬁed, e.g., cell lines, knock-out models, etc. Furthermore, not all
genes in a given pathway are necessarily regulated at the level
of transcription.32
One of the inherent challenges in transcriptome data analy-
sis is to reduce the dimensionality and the complexity of the
data set in a meaningful way without losing critical biological
information. Summarizing genes into transcriptional modules
has become a powerful tool to assess gene networks.51 For our
analyses, we used the BTMs published by Li et al.32 These mod-
ules were constructed by integrating large amounts of publically
available gene expression data generated on peripheral blood
cells. Because these modules were generated from PBMC
expression data, we found the annotation to be more informa-
tive than other available modules and libraries. In addition,
Figure 4. Patients with NK and (T)cell BTM enrichment post CV9201 treatment are associated with a prolonged survival. Kaplan–Meier curves for overall survival (A) and
progression-free survival (C) are shown for patients belonging to cluster 1, 2a and 2b. Overall survival (B) and progression-free survival rates (D) are shown for patients
belonging to cluster 1 compared to patients belonging to cluster 2. Log-rank test was performed to calculate the hazard ratio and p value.
ONCOIMMUNOLOGY e1249560-7
these modules offered sufﬁcient plasticity to be applied to a dis-
ease setting as heterogeneous as lung cancer, while still enabling
us to obtain immunologically relevant information. The use of
BTMs, especially in conjunction with GSEA, is a powerful and
sensitive approach, which yielded novel biological insights
despite our relatively small cohort size.
Using unsupervised clustering based on BTM activity score
changes over time, we identiﬁed a segregation of vaccinated
NSCLC patients into two distinct groups, each with a discrete
molecular signature.We demonstrated that these transcriptional
changes after vaccination correlated with our ﬂow cytometric
phenotyping data as well as the N/L ratio. These ﬁndings suggest
that the gene expression differences could be a result of changes
in the cellular composition of PBMCs although transcriptional
activation of leukocyte subsets cannot be ruled out.
The ﬁrst patient group exhibited an upregulation of myeloid
cell-associated and inﬂammation-related modules, which could
indicate an accumulation of monocytes and other myeloid cells
(e.g., neutrophils) in the periphery. A possible explanation for
this phenomenon could be an enrichment of a heterogeneous
set of immuno-suppressive cells known as MDSCs. MDSCs are
immature myeloid cells that accumulate due to an abnormal
differentiation process in disease settings.52 Expansion of
MDSCs was observed in patients of virtually all cancer types53
including NSCLC.34,54 In general, the frequency of MDSCs in
peripheral blood depends on the tumor burden and elevated
numbers of these cells correlate with disease progression and
overall poor prognosis.55 In addition, the upregulation of mye-
loid cells was accompanied by an enrichment of inﬂammation
and immune activation modules (Fig. 3A). Cancer-related
inﬂammation has long been recognized to be one of the immu-
nological hallmarks of disease and one of the key drivers of
tumor promotion.56,57 Circulating inﬂammation markers were
described to have prognostic capacity in lung cancer.58,59 In
accordance with these observations, we found that all patients
with a transcriptional enrichment of myeloid and immune acti-
vation modules at week 5 died within 1 y. In contrast, patients
belonging to cluster 2 exhibited an upregulation of modules
containing genes reﬂecting T, B and NK cell biology. All long-
term survivors belonged to patient cluster 2. Increased activity
of these modules was associated with a general increase of lym-
phocyte frequencies in peripheral blood. Notably, enriched T
cell modules were associated with a distinct effector memory
CD8C T cell subset with a CD27CCD28¡ phenotype. Effector
memory CD8C T cells are heterogeneous and further subsets
can be delineated based on the surface expression of CD27 and
Figure 5. Changes in the transcriptional signature correlate with changes in lymphocyte subsets. (A) Changes in T cell module activity scores were correlated with
changes in either relative or absolute numbers of CD28¡CD27C effector memory CD8C T cells. (B) Changes in B cell module activity scores were correlated with changes
in relative or absolute numbers of B cells. (C) Myeloid cell modules were correlated with changes in relative or absolute numbers of CD16CCD3¡CD56¡ cells. (D) Changes
in BTM cluster 2a were correlated with changes in lymphocyte frequencies or N/L ratio. (E) Changes in BTM cluster 1 were correlated with changes in lymphocyte frequen-
cies or N/L ratio. Spearman’s rank correlation test was performed for all analyses. Error bars indicate standard deviations of changes in BTM activity scores. EM – effector
memory.
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CD28.60,61 Effector memory CD8C T cells lacking surface
expression of the B7-receptor CD28 are more likely to constitu-
tively produce effector molecules, including granzyme B, per-
forin and IFNg compared to their CD28C counterpart.60 In
support of this notion, we observed an upregulation of a num-
ber of genes associated with T effector functions in cluster 2
patients at week 5 compared to week 0. These genes included
CCL5, CTSW, GZMA, GZMB, GZMH, GZMM, GZMK, PRF1,
KLRF1, TBX21 and LEF1. Importantly, CD28, though part of
several enriched T cell modules in patient cluster 2, was not
among the enriched leading edge genes, which is in accordance
with the ﬁnding that alterations in the T cell module activity
scores correlated with the frequency of CD27CCD28¡ effector
memory CD8C T cells. Although long-term survivors were
characterized by increased T cell module activity scores in com-
parison with short-term survivors, they further exhibited an
upregulation of effector cell modules (predominantly T and
NK cell modules) after treatment.
Our ﬁndings are corroborated by previously published stud-
ies reporting transcriptional analyses of peripheral blood sam-
ples in NSCLC.37,38,62 These studies indicate that lung cancer
induces tumor-speciﬁc molecular signatures, which can be
detected in the periphery. Analysis of prognostic genes, which
are immune cell type-speciﬁc revealed a signiﬁcant association
of myeloid cells and T cells with survival.38,63 All of the 21 mye-
loid cell-associated genes with prognostic value were exclusively
negatively correlated with survival. Among 23 prognostic T cell
genes, eight genes were associated with better survival, includ-
ing LEF1 and GZMK, which were also enriched in our cluster 2
patient group.38 In contrast to our longitudinal study, these
results were generated in a cross-sectional study. In addition,
the study by Kossenkov et al. analyzed NSCLC patients with
clinical stages I–IIIA prior to surgical resection, whereas our
study only included advanced stage IV patients. In spite of this
discrepancy, analogous immune cell-speciﬁc gene signatures
could be identiﬁed indicating similar biological processes in
NSCLC patients at various disease stages. These data are in
accordance with our ﬁnding that long-term survivors com-
pared with short-term survivors displayed elevated of T and
NK cell transcriptional module activity at baseline and subse-
quent time points. We furthermore showed that changes in
activity scores of myeloid cell modules and T cell modules cor-
related with the N/L ratio, a well-established biomarker in vari-
ous cancer indications.42-46 Our data, however, are more
informative than the N/L ratio. For example, we show that
patients in cluster 2 with increases in T and NK cell module
activity scores at week 5 are heterogeneous and can further be
dissected based on expression changes of cell cycle and mitosis
genes. Further studies are required to conﬁrm whether these
signatures can be reproduced in independent study cohorts
and whether changes in cell cycle module activities correlate
with differential clinical outcomes.
Changes in gene expression at week 5 compared to baseline
could reﬂect effects of RNActive treatment, treatment-inde-
pendent differential disease progression or other unknown var-
iables. Notably, most direct transcriptional perturbations in
peripheral blood induced by vaccinations, such as immuniza-
tions against ﬂu antigens, seem to occur rapidly after treatment
(e.g., after 24 h) and are very transient in nature.64,65 In
contrast, our post vaccine blood samples were obtained 2 weeks
after the third or ﬁfth vaccination, respectively. The transcrip-
tional changes over time in our study therefore seem to be the
result of effects lasting in the range of weeks instead of days. It
is tempting to speculate that the increase of T and NK cell mod-
ules at week 5 compared to week 0 could be a result of CV9201
immunotherapy and thus represent a candidate biomarker for
clinical beneﬁt post treatment. In support of this hypothesis,
we found that all long-term survivors were part of patient clus-
ter 2 displaying a further increase of T and NK cell module
activity at week 5 compared to baseline. Conversely, the
increase of myeloid cell- and inﬂammation-related genes in
some patients could reﬂect lung cancer disease progression
since MDSC expansion correlates with tumor burden.
In the absence of an untreated control cohort, we cannot
address the question of whether mRNA-based immunotherapy
with CV9201 can increase T cell gene expression and reduce
myeloid module activity and whether it induces clinical beneﬁt.
In addition, our data set is limited by a relatively small cohort
size as well as the absence of an independent testing cohort,
thus precluding extensive cross-validation or analysis of the
robustness of these molecular signatures. Our ﬁndings certainly
warrant further investigation in randomized controlled clinical
trials. Placebo-controlled clinical trials in NSCLC patients
addressing the clinical efﬁcacy of CV9201 treatment in combi-
nation with chemo- and radiotherapy are currently in prepara-
tion. These studies will allow formal testing of the hypotheses
generated with these initial results, with the aim to identify reli-
able, immunological correlates and biomarkers with predictive
value in cancer immunotherapy.
Material and methods
Two-component mRNA cancer immunotherapy CV9201
CureVac AG proprietary technology has generated mRNA
molecules with increased stability and translatability (patents
EP1392341B1, EP1604688B1). All mRNA vaccines used in the
present study were produced in accordance with this technol-
ogy and Good Manufacturing Practice guidelines (CureVac
AG, T€ubingen, Germany). The RNActive-based vaccine
CV9201 consisted of a mixture of 50% free mRNA (component
1) and 50% mRNA complexed with protamine (MEDA
Pharma) at a weight ratio of 2:1 (component 2). First, mRNA
was complexed by the addition of protamine-Ringer lactate
solution and, after stable complexation, free mRNA was
added.19 CV9201 consists of RNActive-based mRNA compo-
nents encoding the NSCLC-speciﬁc antigens NY-ESO1,
MAGE-C1, MAGE-C2, Survivin, and 5T4. The ﬁve antigens
were formulated separately.
Patients and study design
Study participants were at least 18 y of age with advanced, stage
IIIB or IV NSCLC (UICC V6.0 criteria) with stable disease or
objective response according to Response Evaluation Criteria
in Solid Tumors (RECIST), version 1.0, after ﬁrst-line treat-
ment (chemotherapy, chemo-radiotherapy) for advanced,
unresectable or metastatic disease.66 Patients must have had a
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life expectancy of >6 mo as assessed by the investigator. Eligi-
bility criteria further included an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of  1 and adequate
renal, hepatic, cardiac and bone marrow function. Informed
consent was obtained from all patients prior to any study-
related procedures. The study was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice
guidelines and was registered at the European Clinical Trials
Database with EudraCT number 2008-007785-39. The protocol
was approved by ethics committees/review boards of participat-
ing study sites. The primary objective of the clinical trial was
assessment of safety and secondary objectives were evaluation
of induction of immune responses.
Patients were vaccinated at weeks 1, 2, 3, 5 and 7 with
320 mg mRNA of each antigen for a total dose of 1,600 mg
mRNA per vaccination. Two intradermal injections of each
antigen were applied to two injections sites, one into the thigh
and one into the upper arm of the same body half. Injection
sites of each antigen were rotated clockwise at different vaccina-
tion days. After end or discontinuation of vaccination, further
antitumor therapy was at the discretion of the investigator.
Peripheral blood sampling was performed at day 0 (baseline),
week 5 (2 weeks post third vaccination) and week 9 (2 weeks
post 5th vaccination). Transcriptome proﬁling analysis was
restricted to stage IV NSCLC patients treated in the phase IIa
part of the study and subjects were chosen based on sample
availability. Demographic patient data is provided in Table 1 as
well as Table S1.
Preparation of peripheral blood mononuclear cells
(PBMCs)
To accommodate the challenges underlying a multi-centric
clinical trial and to consistently ensure a high quality of cells,
PBMC preparation from blood samples was required to be per-
formed within 6 h after venipuncture. A study-speciﬁc and
standardized PBMC preparation kit (Interlab GmbH, Ger-
many) containing all necessary materials, buffers and media
was used and PBMC puriﬁcation were carried out by trained
personnel in validated central laboratories according to stan-
dard operating procedures (SOPs). Brieﬂy, blood was trans-
ferred from heparin tubes to Leucosep tubes and centrifuged.
PBMCs were harvested from the interphase and washed twice.
Viability was assessed by Trypan Blue staining, yield and red
blood cell contamination was assessed by Tuerk’s solution for
cell counting. After cell counting, PBMCs were slowly frozen in
serum-free Cryo SFM media (Promocell, Heidelberg, Ger-
many) using Mr. Frosty freezing devices (VWR, Darmstadt,
Germany) at ¡80 for 24 h before transferring frozen cells to
liquid nitrogen. Blood neutrophil and lymphocyte counts were
determined from peripheral blood using validated diagnostic
assays at a central laboratory provider (InterLab Services world-
wide GmbH, Munich, Germany).
Gene expression proﬁling
RNA was isolated from re-thawed PBMCs frozen in PBS using
RNEasy (Qiagen) according to the manufacturer’s instructions.
To ensure that re-thawing of PBMC samples did not affect any
down-stream analyses, RNA quality control was performed on
a 2100 Bioanalyzer (Agilent Technologies) and only samples
with a RIN value 6.5 were further processed. Cyanine-3-label-
ing of cRNA and hybridization using the Agilent SurePrint G3
Human Gene Expression 8£60K v2 Microarray platform was
performed by IMGM, Munich, Germany according to
manufacturer’s manuals (Agilent Technologies). Raw data was
processed using Feature Extraction 10.7.3.1 and GeneSpring
GX 12.6.1. Quantile normalization was performed and log2-
transformed data was ﬁltered for probes detectable in at least
one sample resulting in gene expression data for 48,605 probes.
Calculation of blood transcriptional module (BTM) activity
scores and gene set enrichment analysis (GSEA)
To address the expected heterogeneity of the samples derived
from individual patients, we sought to apply a modular
approach to gene expression analysis developed by Li et al.32
These 346 BTMs represent sets of genes, which are transcrip-
tionally coordinately expressed. Most of these BTMs reﬂect sets
of genes involved in the regulation of an immunological pro-
cess, such as signaling pathways or represent sets of genes
speciﬁcally enriched in immune cells, such as T or B cells. BTM
activity scores were determined, which represent the mean
expression of all genes contained in a module. Following the
example of Li et al. probes with the highest average expression
across all samples were chosen for genes targeted by multiple
probes.32
GSEA was performed as described previously.67 Ranking of
gene lists was performed using unpaired Student’s t-test for
cross-sectional comparisons. For longitudinal contrasts,
pre-ranked gene lists were generated based on t scores obtained
from paired Student’s t-test analyses.
Phenotyping of lymphocyte subsets
After thawing PBMCs in PBS containing the endonuclease ben-
zonase (Novagen/Merck Milipore Schwalbach, Germany), cells
were directly stained in PBEA buffer (PBS, 0.5% BSA, 2 mM
EDTA and 0.01% NaN3 ) for 30 min on 4C. An overview of
the B cell-, T cell- and NK cell/regulatory T cell (Treg)-pheno-
typing panels including ﬂuorochromes is provided in Table S2.
Cells were washed with PBEA buffer and ﬁxed in PBS contain-
ing 1% formaldehyde. The following monoclonal antibodies
were used after initial testing and titration: anti-CD3 Alexa-
eFluor 780, anti-CD4 PE-Cy7, anti-CD19 Pe-Cy7, anti-CD27
APC, anti-CD28 FITC, and anti-CCR7 PE (eBioscience, San-
Diego, USA), anti-CD4 PerCP-Cy5.5, anti-CD8C PerCP-Cy5.5,
anti-CD16 PerCP-Cy5.5, anti-CD20 FITC, anti-CD25 V450,
anti-CD38 PerCP-Cy5.5, anti-CD45RA HV450, anti-CD69
FITC, anti-CD86 V450, anti-IFN-g APC, anti-IgD PE,
anti-TNF-a FITC (Becton Dickenson GmbH, Heidelberg,
Germany), anti-IL-2 PaciﬁcBlue (BioLegend,); anti-CD56 PE
(Miltenyi, Bergisch Gladbach, Germany).
Flow cytometry
All ﬂow cytometric measurements were performed on a
calibrated FACSCanto II (4-2-2) cytometer (Becton Dickenson,
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Heidelberg, Germany). Acquisition of data including compen-
sation was performed using BD FACSDiva 6.1 and use of
compensation beads. Accumulated data was analyzed using
FlowJo versions 7.5.2 and 10.0.7. (Treestar Inc., Oregon, USA).
Tethered and non-viable cells were excluded from analysis.
Absolute cell counts from lymphocyte subpopulations were
determined by normalizing data to lymphocyte counts derived
from differential blood tests. All laboratory procedures were
performed according to approved SOPs.
Statistical analysis
Differentially expressed genes between groups were determined
based on false discovery rate (FDR)-corrected p-values in com-
bination with fold change (FC) thresholds. In detail, p values
were generated by the Welch’s approximate t-test followed by
the Benjamini and Hochberg correction for multiple testing
using GeneSpring G x 12.6.1. FC thresholds of ranging from
1.5 to 3 were applied in our analysis. Hierarchical clustering,
calculation of t values of paired t-tests and PCA were per-
formed using MeV version 4.9.0. Unsupervised hierarchical
clustering of BTM activity scores was performed using Euclid-
ean distance and average linkage clustering. Survival analyses
including Log-rank test were performed with GraphPad Prism
version 6.0.5. GraphPad Prism was also used to plot all graphs
except for heatmaps and to perform Pearson and Spearman’s
rank correlation analyses.
Disclosure of potential conﬂicts of interest
HSH, SDK, BS, UGV, AS, KJK, VW, IH, MFM are or were employed at
CureVac AG. HSH, SDK and MFM are named as inventors on a patent
application for a gene expression-based biomarker ﬁled by CureVac AG.
Acknowledgments
We thank all participating medical doctors (Martin Sebastian, Lotta v.
Boehmer, Alfred Zippelius, Frank Mayer, Martin Reck, Djordje Atanack-
ovic, Michael Thomas, Folker Schneller, Jan Stoehlmacher, Eray Goekkurt,
Helga Bernhard, Andreas Gr€oschel, Robert Bals, Susanne Schmidt, Elke
J€ager and Alexander Knuth) and staff of the participating hospitals and
importantly all participating patients. Helen Dietrich and Simone Eppler
provided excellent technical support with phenotypic analyses by ﬂow
cytometry. We acknowledge Fatma Doener and Madeleine Hipp for criti-
cal review of our manuscript and for helpful discussions.
Author contributions
HSH, SDK, MF conceived the study; HSH, LD, OK, JBM analyzed the data;
BS, UGK, AS, KJK, VW, IH were responsible for the clinical trial and pro-
vided clinical material and data; HSH, SDK and JBM wrote the manu-
script; all authors read and discussed the manuscript.
ORCID
James M. Billingsley http://orcid.org/0000-0003-0928-1454
References
1. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-
small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer
2014; 14:535-46; PMID:25056707; http://dx.doi.org/10.1038/nrc3775
2. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E,
Ramalingam SS. Lung cancer in elderly patients: an analysis of the sur-
veillance, epidemiology, and end results database. J Clin Oncol 2007;
25:5570-7; PMID:18065729; http://dx.doi.org/10.1200/JCO.2007.12.5435
3. Reck M. What future opportunities may immuno-oncology provide
for improving the treatment of patients with lung cancer? Ann Oncol
2012; 23 Suppl 8:viii28-34; PMID:22918925; http://dx.doi.org/
10.1093/annonc/mds260
4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of
age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/
10.1038/nature10673
5. Chen DS, Mellman I. Oncology meets immunology: the cancer-
immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.
doi.org/10.1016/j.immuni.2013.07.012
6. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP,
Patnaik A, Aggarwal C, Gubens M, Horn L et al. Pembrolizumab for the
treatment of non-small-cell lung cancer. N Engl J Med 2015; 372:2018-
28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa1501824
7. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past,
present, and future. J Clin Invest 2015; 125:3384-91; PMID:26325035;
http://dx.doi.org/10.1172/JCI80011
8. Topalian SL, Sharpe AH. Balance and imbalance in the immune sys-
tem: life on the edge. Immunity 2014; 41:682-4; PMID:25517610;
http://dx.doi.org/10.1016/j.immuni.2014.11.005
9. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD,
Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined
Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/
10.1056/NEJMoa1504030
10. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Feher-
vari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3C regula-
tory T cell function. Science 2008; 322:271-5; PMID:18845758; http://
dx.doi.org/10.1126/science.1160062
11. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T
cell responses against melanoma. Annu Rev Immunol 2006; 24:175-
208; PMID:16551247; http://dx.doi.org/10.1146/annurev.immunol.
24.021605.090733
12. Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Thera-
peutic cancer vaccines. J Clin Invest 2015; 125:3401-12;
PMID:26214521; http://dx.doi.org/10.1172/JCI80009
13. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S,
Thatcher N, Wagstaff J, Zielinski C, Faulkner I et al. Therapeutic
vaccines for cancer: an overview of clinical trials. Nat Rev Clin
Oncol 2014; 11:509-24; PMID:25001465; http://dx.doi.org/10.1038/
nrclinonc.2014.111
14. Sahin U, Kariko K, Tureci O. mRNA-based therapeutics–developing a
new class of drugs. Nat Rev Drug Discov 2014; 13:759-80;
PMID:25233993; http://dx.doi.org/10.1038/nrd4278
15. Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A,
Baumhof P, Scheel B, Koch SD, Fotin-Mleczek M. A novel, disruptive
vaccination technology: self-adjuvanted RNActive((R)) vaccines.
Hum Vaccin Immunother 2013; 9:2263-76; PMID:23921513; http://
dx.doi.org/10.4161/hv.25181
16. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira
S, Lipford G, Wagner H, Bauer S. Species-speciﬁc recognition of sin-
gle-stranded RNA via toll-like receptor 7 and 8. Science 2004;
303:1526-9; PMID:14976262; http://dx.doi.org/10.1126/science.
1093620
17. Scheel B, Braedel S, Probst J, Carralot JP, Wagner H, Schild H, Jung G,
Rammensee HG, Pascolo S. Immunostimulating capacities of stabi-
lized RNA molecules. Eur J Immunol 2004; 34:537-47; PMID:
14768059; http://dx.doi.org/10.1002/eji.200324198
18. Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A,
Duchardt KM, Kallen KJ. Highly potent mRNA based cancer vaccines
represent an attractive platform for combination therapies supporting
ONCOIMMUNOLOGY e1249560-11
an improved therapeutic effect. J Gene Med 2012; 14:428-39;
PMID:22262664; http://dx.doi.org/10.1002/jgm.2605
19. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S,
Probst J, Kallen KJ. Messenger RNA-based vaccines with dual activity
induce balanced TLR-7 dependent adaptive immune responses and
provide antitumor activity. J Immunother 2011; 34:1-15; PMID:
21150709; http://dx.doi.org/10.1097/CJI.0b013e3181f7dbe8
20. Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG, Pascolo
S. Spontaneous cellular uptake of exogenous messenger RNA in vivo is
nucleic acid-speciﬁc, saturable and ion dependent. Gene Ther 2007;
14:1175-80; PMID:17476302; http://dx.doi.org/10.1038/sj.gt.3302964
21. Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG,
Weller M, Pascolo S. Therapeutic anti-tumor immunity triggered by
injections of immunostimulating single-stranded RNA. Eur J Immu-
nol 2006; 36:2807-16; PMID:17013976; http://dx.doi.org/10.1002/
eji.200635910
22. Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, Rammensee HG,
Pascolo S. Polarization of immunity induced by direct injection of naked
sequence-stabilized mRNA vaccines. Cell Mol Life Sci 2004; 61:2418-24;
PMID:15378210; http://dx.doi.org/10.1007/s00018-004-4255-0
23. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004;
4:1285-94; PMID:15268662; http://dx.doi.org/10.1517/14712598.4.8.1285
24. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA
leads to induction of speciﬁc cytotoxic T lymphocytes and antibodies.
Eur J Immunol 2000; 30:1-7; PMID:10602021; http://dx.doi.org/
10.1002/1521-4141(200001)30:1%3c1::AID-IMMU1%3e3.0.CO;2-
25. Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P,
Scheel B, Voss S, Kallen KJ, Fotin-Mleczek M. A novel RNA-based
adjuvant combines strong immunostimulatory capacities with a favor-
able safety proﬁle. Int J Cancer 2015; 137(2):372-84; PMID:25530186;
http://dx.doi.org/10.1002/ijc.29402
26. Kubler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W,
Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L et al. Self-
adjuvanted mRNA vaccination in advanced prostate cancer patients: a
ﬁrst-in-man phase I/IIa study. J Immunother Cancer 2015; 3:26;
PMID:26082837; http://dx.doi.org/10.1186/s40425-015-0068-y
27. Chaussabel D, Pascual V, Banchereau J. Assessing the human immune
system through blood transcriptomics. BMC Biol 2010; 8:84;
PMID:20619006; http://dx.doi.org/10.1186/1741-7007-8-84
28. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D,
Pirani A, Gernert K, Deng J, Marzolf B et al. Systems biology approach
predicts immunogenicity of the yellow fever vaccine in humans. Nat
Immunol 2009; 10:116-25; PMID:19029902; http://dx.doi.org/
10.1038/ni.1688
29. Furman D, Jojic V, Kidd B, Shen-Orr S, Price J, Jarrell J, Tse T, Huang
H, Lund P, Maecker HT et al. Apoptosis and other immune bio-
markers predict inﬂuenza vaccine responsiveness. Mol Syst Biol 2013;
9:659; PMID:23591775; http://dx.doi.org/10.1038/msb.2013.15
30. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-
Mouhim A, Moser JM, Mehta RS, Drake DR 3rd, Castro E et al. Yel-
low fever vaccine induces integrated multilineage and polyfunctional
immune responses. J Exp Med 2008; 205:3119-31; PMID:19047440;
http://dx.doi.org/10.1084/jem.20082292
31. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining
WN, Means AR, Kasturi SP, Khan N, Li GM et al. Systems biology of
vaccination for seasonal inﬂuenza in humans. Nat Immunol 2011;
12:786-95; PMID:21743478; http://dx.doi.org/10.1038/ni.2067
32. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S,
Davis C, Schmidt DS, Johnson SE, Milton A, Rajam G et al. Molecular
signatures of antibody responses derived from a systems biology study
of ﬁve human vaccines. Nat Immunol 2014; 15:195-204; PMID:
24336226; http://dx.doi.org/10.1038/ni.2789
33. Chaussabel D, Baldwin N. Democratizing systems immunology with
modular transcriptional repertoire analyses. Nat Rev Immunol 2014;
14:271-80; PMID:24662387; http://dx.doi.org/10.1038/nri3642
34. Heuvers ME, Muskens F, Bezemer K, Lambers M, Dingemans AM,
Groen HJ, Smit EF, Hoogsteden HC, Hegmans JP, Aerts JG. Arginase-1
mRNA expression correlates with myeloid-derived suppressor cell levels
in peripheral blood of NSCLC patients. Lung Cancer 2013; 81:468-74;
PMID:23850196; http://dx.doi.org/10.1016/j.lungcan.2013.06.005
35. Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A,
Skalidaki E, Mavroudis D, Georgoulias V, Kotsakis A. A circulating
subpopulation of monocytic myeloid-derived suppressor cells as an
independent prognostic/predictive factor in untreated non-small lung
cancer patients. J Immunol Res 2014; 2014:659294; PMID:25436215;
http://dx.doi.org/10.1155/2014/659294
36. Schneider T, Sevko A, Heussel CP, Umansky L, Beckhove P, Diene-
mann H, Saﬁ S, Utikal J, Hoffmann H, Umansky V. Serum inﬂamma-
tory factors and circulating immunosuppressive cells are predictive
markers for efﬁcacy of radiofrequency ablation in non-small-cell lung
cancer. Clin Exp Immunol 2015; 180(3):467-74; PMID:25644608
37. Showe MK, Vachani A, Kossenkov AV, Yousef M, Nichols C,
Nikonova EV, Chang C, Kucharczuk J, Tran B, Wakeam E et al. Gene
expression proﬁles in peripheral blood mononuclear cells can
distinguish patients with non-small cell lung cancer from patients
with nonmalignant lung disease. Cancer Res 2009; 69:9202-10; PMID:
19951989; http://dx.doi.org/10.1158/0008-5472.CAN-09-1378
38. Kossenkov AV, Dawany N, Evans TL, Kucharczuk JC, Albelda SM,
Showe LC, Showe MK, Vachani A. Peripheral immune cell gene
expression predicts survival of patients with non-small cell lung can-
cer. PLoS One 2012; 7:e34392; PMID:22479623; http://dx.doi.org/
10.1371/journal.pone.0034392
39. Zhou C, Licciulli S, Avila JL, Cho M, Troutman S, Jiang P, Kossenkov
AV, Showe LC, Liu Q, Vachani A et al. The Rac1 splice form Rac1b
promotes K-ras-induced lung tumorigenesis. Oncogene 2013; 32:903-
9; PMID:22430205; http://dx.doi.org/10.1038/onc.2012.99
40. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of
memory T lymphocytes with distinct homing potentials and effector
functions. Nature 1999; 401:708-12; PMID:10537110; http://dx.doi.
org/10.1038/44385
41. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein
MR, van Lier RA. Phenotypic and functional separation of memory and
effector human CD8C T cells. J Exp Med 1997; 186:1407-18;
PMID:9348298; http://dx.doi.org/10.1084/jem.186.9.1407
42. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Preoperative
neutrophil to lymphocyte ratio as a prognostic predictor after curative
resection for non-small cell lung cancer. Anticancer Res 2011;
31:2995-8; PMID:21868550
43. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN.
Blood neutrophil-to-lymphocyte ratio predicts survival in patients
with colorectal liver metastases treated with systemic chemotherapy.
Ann Surg Oncol 2009; 16:614-22; PMID:19130139; http://dx.doi.org/
10.1245/s10434-008-0267-6
44. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte
ratio predicts chemotherapy outcomes in patients with advanced colo-
rectal cancer. Br J Cancer 2011; 104:1288-95; PMID:21448173; http://
dx.doi.org/10.1038/bjc.2011.100
45. Li J, Jiang R, Liu WS, Liu Q, Xu M, Feng QS, Chen LZ, Bei JX, Chen
MY, Zeng YX. A large cohort study reveals the association of elevated
peripheral blood lymphocyte-to-monocyte ratio with favorable prog-
nosis in nasopharyngeal carcinoma. PLoS One 2013; 8:e83069;
PMID:24386144; http://dx.doi.org/10.1371/journal.pone.0083069
46. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Korn-
prat P, AlZoughbi W, Seggewies FS, Lackner C et al. Increased neutro-
phil-lymphocyte ratio is a poor prognostic factor in patients with
primary operable and inoperable pancreatic cancer. Br J Cancer 2013;
109:416-21; PMID:23799847; http://dx.doi.org/10.1038/bjc.2013.332
47. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity 2010;
33:516-29; PMID:21029962; http://dx.doi.org/10.1016/j.immuni.
2010.10.006
48. Quackenbush J. Computational analysis of microarray data. Nat Rev
Genet 2001; 2:418-27; PMID:11389458; http://dx.doi.org/10.1038/
35076576
49. Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis:
from disarray to consolidation and consensus. Nat Rev Genet 2006;
7:55-65; PMID:16369572; http://dx.doi.org/10.1038/nrg1749
50. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current
approaches and outstanding challenges. PLoS Comput Biol 2012;
8:e1002375; PMID:22383865; http://dx.doi.org/10.1371/journal.pcbi.
1002375
e1249560-12 H. S. HONG ET AL.
51. Friedman N. Inferring cellular networks using probabilistic graphical
models. Science 2004; 303:799-805; PMID:14764868; http://dx.doi.
org/10.1126/science.1094068
52. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor
cells. Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx.doi.
org/10.1038/nrc3581
53. Condamine T, Ramachandran I, Youn JI, Gabrilovich DI. Regulation
of tumor metastasis by myeloid-derived suppressor cells. Annu Rev
Med 2015; 66:97-110; PMID:25341012; http://dx.doi.org/10.1146/
annurev-med-051013-052304
54. de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ,
Smit EF, Hoogsteden HC, Hendriks RW, Aerts JG, Hegmans JP.
Immunoglobulin-like transcript 3 is expressed by myeloid-derived
suppressor cells and correlates with survival in patients with
non-small cell lung cancer. Oncoimmunology 2015; 4:e1014242;
PMID:26140237; http://dx.doi.org/10.1080/2162402X.2015.1014242
55. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole
DJ, Montero AJ. Increased circulating myeloid-derived suppressor
cells correlate with clinical cancer stage, metastatic tumor burden, and
doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol
Immunother 2009; 58:49-59; PMID:18446337; http://dx.doi.org/
10.1007/s00262-008-0523-4
56. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.
cell.2011.02.013
57. Crusz SM, Balkwill FR. Inﬂammation and cancer: advances and new
agents. Nat Rev Clin Oncol 2015; 12(10):584-96; PMID:26122183
58. Jiang AG, Chen HL, Lu HY. The relationship between glasgow
prognostic score and serum tumor markers in patients with advanced
non-small cell lung cancer. BMC Cancer 2015; 15:386; PMID:
25956656; http://dx.doi.org/10.1186/s12885-015-1403-x
59. Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E,
Schussler O, Dermine H, Regnard JF, Burroni B et al. Systemic inﬂam-
mation, nutritional status and tumor immune microenvironment
determine outcome of resected non-small cell lung cancer. PLoS One
2014; 9:e106914; PMID:25238252; http://dx.doi.org/10.1371/journal.
pone.0106914
60. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM,
Corthesy P, Devevre E, Speiser DE, Rufer N. Four functionally distinct
populations of human effector-memory CD8C T lymphocytes. J
Immunol 2007; 178:4112-9; PMID:17371966; http://dx.doi.org/
10.4049/jimmunol.178.7.4112
61. Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec
G. Multiparameter ﬂow cytometric analysis of CD4 and CD8 T cell
subsets in young and old people. Immun Ageing 2008; 5:6; PMID:
18657274; http://dx.doi.org/10.1186/1742-4933-5-6
62. Kossenkov AV, Vachani A, Chang C, Nichols C, Billouin S, Horng W,
RomWN, Albelda SM, Showe MK, Showe LC. Resection of non-small
cell lung cancers reverses tumor-induced gene expression changes in
the peripheral immune system. Clin Cancer Res 2011; 17:5867-77;
PMID:21807633; http://dx.doi.org/10.1158/1078-0432.CCR-11-0737
63. Showe MK, Kossenkov AV, Showe LC. The peripheral immune
response and lung cancer prognosis. Oncoimmunology 2012; 1:1414-
6; PMID:23243612; http://dx.doi.org/10.4161/onci.21096
64. Sobolev O, Binda E, O’Farrell S, Lorenc A, Pradines J, Huang Y,
Duffner J, Schulz R, Cason J, Zambon M et al. Adjuvanted inﬂuenza-
H1N1 vaccination reveals lymphoid signatures of age-dependent early
responses and of clinical adverse events. Nat Immunol 2016; 17:204-
13; PMID:26726811; http://dx.doi.org/10.1038/ni.3328
65. Nakaya HI, Hagan T, Duraisingham SS, Lee EK, Kwissa M, Rouphael
N, Frasca D, Gersten M, Mehta AK, Gaujoux R et al. Systems analysis
of immunity to inﬂuenza vaccination across multiple years and in
diverse populations reveals shared molecular signatures. Immunity
2015; 43:1186-98; PMID:26682988; http://dx.doi.org/10.1016/j.
immuni.2015.11.012
66. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS,
Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT,
Christian MC et al. New guidelines to evaluate the response to
treatment in solid tumors. European Organization for Research
and Treatment of Cancer, National Cancer Institute of the United
States, National Cancer Institute of Canada. J Natl Cancer Inst
2000; 92:205-16; PMID:10655437; http://dx.doi.org/10.1093/jnci/
92.3.205
67. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette
MA, PaulovichA, Pomeroy SL,GolubTR, Lander ES et al. Gene set enrich-
ment analysis: a knowledge-based approach for interpreting genome-wide
expression proﬁles. Proc Natl Acad Sci U S A 2005; 102:15545-50;
PMID:16199517; http://dx.doi.org/10.1073/pnas.0506580102
ONCOIMMUNOLOGY e1249560-13
